{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:26:22Z","timestamp":1777775182361,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["BIO2016-76063-R"],"award-info":[{"award-number":["BIO2016-76063-R"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PID2019-105416RB-I00"],"award-info":[{"award-number":["PID2019-105416RB-I00"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d&apos;Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["FI_B2_00051"],"award-info":[{"award-number":["FI_B2_00051"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d&apos;Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["SLT002\/16\/00433"],"award-info":[{"award-number":["SLT002\/16\/00433"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d&apos;Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017-SGR-865"],"award-info":[{"award-number":["2017-SGR-865"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d&apos;Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017 FI_B 00680"],"award-info":[{"award-number":["2017 FI_B 00680"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d&apos;Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017-SGR-1395"],"award-info":[{"award-number":["2017-SGR-1395"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d&apos;Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017SGR-229"],"award-info":[{"award-number":["2017SGR-229"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005053","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Bioingenier\u00eda, Biomateriales y Nanomedicina","doi-asserted-by":"publisher","award":["CB06\/01\/1031"],"award-info":[{"award-number":["CB06\/01\/1031"]}],"id":[{"id":"10.13039\/501100005053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008050","name":"Fundaci\u00f3n Cellex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017167","name":"International Centre for Theoretical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["FIS PI17\/01246"],"award-info":[{"award-number":["FIS PI17\/01246"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI20\/00400"],"award-info":[{"award-number":["PI20\/00400"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PIE15\/00028"],"award-info":[{"award-number":["PIE15\/00028"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["RD16\/0011\/0028"],"award-info":[{"award-number":["RD16\/0011\/0028"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CP19\/00028"],"award-info":[{"award-number":["CP19\/00028"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI18\/00650"],"award-info":[{"award-number":["PI18\/00650"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI15\/00378"],"award-info":[{"award-number":["PI15\/00378"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003741","name":"Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020618","name":"Institut de Recerca contra la Leuc\u00e8mia Josep Carreras","doi-asserted-by":"publisher","award":["201 941-30-31-3 2"],"award-info":[{"award-number":["201 941-30-31-3 2"]}],"id":[{"id":"10.13039\/501100020618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.biomaterials.2021.121258","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T17:27:49Z","timestamp":1637774869000},"page":"121258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model"],"prefix":"10.1016","volume":"280","author":[{"given":"Victor","family":"Pallar\u00e8s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-2266","authenticated-orcid":false,"given":"Ugutz","family":"Unzueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-2265","authenticated-orcid":false,"given":"A\u00efda","family":"Falg\u00e0s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Avi\u00f1\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y\u00e1iza","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabel","family":"Garc\u00eda-Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"S\u00e1nchez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naroa","family":"Serna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3449-7820","authenticated-orcid":false,"given":"Lorena","family":"Alba-Castell\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"\u00c1lamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4354-3411","authenticated-orcid":false,"given":"L\u00eddia","family":"Ced\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5383-9334","authenticated-orcid":false,"given":"Ramon","family":"Eritja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Villaverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isolda","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2661-9525","authenticated-orcid":false,"given":"Ramon","family":"Mangues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2021.121258_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2021.121258_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.biomaterials.2021.121258_bib3","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/03007995.2019.1631149","article-title":"Side effects from acute myeloid leukemia treatment: results from a national survey","volume":"35","author":"Crossnohere","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.biomaterials.2021.121258_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ajh.23661","article-title":"Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes","volume":"89","author":"Buckley","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biomaterials.2021.121258_bib5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.biomaterials.2021.121258_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11095-019-2654-z","article-title":"Recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia","volume":"36","author":"Chen","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biomaterials.2021.121258_bib7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biomaterials.2021.121258_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719860645","article-title":"Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches","volume":"10","author":"Winer","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.biomaterials.2021.121258_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081983","article-title":"New targeted agents in acute myeloid leukemia: new hope on the rise","volume":"20","author":"Bohl","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2021.121258_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2125.1979.tb01005.x","article-title":"Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia","volume":"8","author":"Harris","year":"1979","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biomaterials.2021.121258_bib11","first-page":"219","article-title":"Pharmacokinetics and metabolism of anthracyclines","volume":"17","author":"Robert","year":"1993","journal-title":"Cancer Surv."},{"key":"10.1016\/j.biomaterials.2021.121258_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/mabs.1.3.8515","article-title":"Antibody drug-conjugates targeting the tumor vasculature: current and future developments","volume":"1","author":"Gerber","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.biomaterials.2021.121258_bib13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/aps.2018.33","article-title":"Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy \u2013 an illustration with firsthand examples","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biomaterials.2021.121258_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/1559325819887048","article-title":"Targeting approaches of nanomedicines in acute myeloid leukemia","volume":"17","author":"Huang","year":"2019","journal-title":"Dose-Response"},{"key":"10.1016\/j.biomaterials.2021.121258_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1389201016666150817095045","article-title":"The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status","volume":"17","author":"Sauvage","year":"2016","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.biomaterials.2021.121258_bib16","first-page":"4533","article-title":"Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles","volume":"7","author":"Unzueta","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2021.121258_bib17","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1002\/cam4.2535","article-title":"Prognostic significance of CXCR4 expression in acute myeloid leukemia","volume":"8","author":"Du","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.biomaterials.2021.121258_bib18","first-page":"98","article-title":"Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia","author":"Cao","year":"2019","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.biomaterials.2021.121258_bib19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2006-05-024844","article-title":"CXCR4 is a prognostic marker in acute myelogenous leukemia","volume":"109","author":"Spoo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2021.121258_bib20","first-page":"79","article-title":"The prognostic value of CXCR4 in acute myeloid leukemia","volume":"21","author":"Ahn","year":"2013","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"10.1016\/j.biomaterials.2021.121258_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.clml.2013.05.013","article-title":"CXCR4 expression, CXCR4 activation, and wild type NPM1 are independently associated with unfavorable prognosis in patients with acute myeloid leukemia","volume":"13","author":"Konoplev","year":"2013","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.biomaterials.2021.121258_bib22","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.22510","article-title":"Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype","volume":"109","author":"Konoplev","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.biomaterials.2021.121258_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7150\/thno.5150","article-title":"Role of CXCR4 in the pathogenesis of acute myeloid leukemia","volume":"3","author":"Peled","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2021.121258_bib24","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2147\/CMAR.S234883","article-title":"Significance of CXCL12\/CXCR4 ligand\/receptor Axis in various aspects of acute myeloid leukemia","volume":"12","author":"Yazdani","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.biomaterials.2021.121258_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-020-00863-9","article-title":"An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination","volume":"13","author":"Pallar\u00e8s","year":"2020","journal-title":"J. Hematol. Oncol.J Hematol Oncol."},{"key":"10.1016\/j.biomaterials.2021.121258_bib26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/bc5000109","article-title":"Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate","volume":"25","author":"Kim","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.biomaterials.2021.121258_bib27","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/cancers13050966","article-title":"Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers","volume":"13","author":"Di Francia","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2021.121258_bib28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003088-200241100-00002","article-title":"Clinical pharmacokinetics of cytarabine formulations","volume":"41","author":"Hamada","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biomaterials.2021.121258_bib29","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/1042819032000159861","article-title":"Problems related to resistance to cytarabine in acute myeloid leukemia","volume":"45","author":"Cros","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biomaterials.2021.121258_bib30","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3324\/haematol.2018.211490","article-title":"A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models","volume":"105","author":"Falg\u00e0s","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.biomaterials.2021.121258_bib31","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.1038\/sj.onc.1206135","article-title":"Structure and function of nucleases in DNA repair: shape, grip and blade of the DNA scissors","volume":"21","author":"Nishino","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.biomaterials.2021.121258_bib32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood-2004-02-0566","article-title":"Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia","volume":"104","author":"Rombouts","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2021.121258_bib33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2008.10.014","article-title":"Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia","volume":"33","author":"Tavernier-Tardy","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biomaterials.2021.121258_bib34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.leukres.2008.11.007","article-title":"CXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you","volume":"33","author":"Burger","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biomaterials.2021.121258_bib35","doi-asserted-by":"crossref","DOI":"10.7754\/Clin.Lab.2019.190725","article-title":"Association of CXCR4 expression and clinical outcome in different subsets of de novo acute myeloid leukemia patients","volume":"66","author":"Rady","year":"2020","journal-title":"Clin. Lab."},{"key":"10.1016\/j.biomaterials.2021.121258_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/leu.2008.299","article-title":"CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers","volume":"23","author":"Burger","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.biomaterials.2021.121258_bib37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1365-2141.2003.04466.x","article-title":"CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis)","volume":"122","author":"Burger","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biomaterials.2021.121258_bib38","doi-asserted-by":"crossref","first-page":"107684","DOI":"10.1016\/j.celrep.2020.107684","article-title":"CXCR4 signaling has a CXCL12-independent essential role in murine MLL-AF9-driven acute myeloid leukemia","volume":"31","author":"Ramakrishnan","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.biomaterials.2021.121258_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00444","article-title":"Acute myeloid leukemia and the bone marrow niche\u2014take a closer look","volume":"8","author":"Behrmann","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2021.121258_bib40","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2021.121258_bib41","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","article-title":"Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100","volume":"113","author":"Nervi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2021.121258_bib42","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/0008-5472.CAN-03-3693","article-title":"CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD\/SCID mice","volume":"64","author":"Tavor","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2021.121258_bib43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.leu.2402431","article-title":"Migratory behavior of leukemic cells from acute myeloid leukemia patients","volume":"16","author":"Voermans","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.biomaterials.2021.121258_bib44","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1182\/blood.V91.12.4523","article-title":"The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1","volume":"91","author":"M\u00f6hle","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2021.121258_bib45","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2008.238","article-title":"The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation","volume":"22","author":"Tavor","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.biomaterials.2021.121258_bib46","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1541-7786.MCR-13-0114","article-title":"Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML","volume":"11","author":"Sison","year":"2013","journal-title":"Mol. Cancer Res. MCR."},{"key":"10.1016\/j.biomaterials.2021.121258_bib47","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1182\/blood.V122.21.5409.5409","article-title":"Characterization of leukemic stem cells in AML cell lines using ALDH staining","volume":"122","author":"Lira Ben\u00edcio","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2021.121258_bib48","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/17425247.2010.527330","article-title":"Development of cytarabine prodrugs and delivery systems for leukemia treatment","volume":"7","author":"Chhikara","year":"2010","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.biomaterials.2021.121258_bib49","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.addr.2004.02.014","article-title":"Nanoparticle and targeted systems for cancer therapy","volume":"56","author":"Brannon-Peppas","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2021.121258_bib50","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2021.121258_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/nano10020276","article-title":"Nanocarriers as magic bullets in the treatment of leukemia","volume":"10","author":"Houshmand","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.biomaterials.2021.121258_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/180549","article-title":"Protein nanoparticles as drug delivery carriers for cancer therapy","volume":"2014","author":"Lohcharoenkal","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.biomaterials.2021.121258_bib53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","article-title":"Ligand-targeted liposome design: challenges and fundamental considerations","volume":"32","author":"Noble","year":"2014","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.biomaterials.2021.121258_bib54","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.nano.2016.04.003","article-title":"Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models","volume":"12","author":"C\u00e9spedes","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biomaterials.2021.121258_bib55","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1073\/pnas.1105351108","article-title":"Designing super selectivity in multivalent nano-particle binding","volume":"108","author":"Martinez-Veracoechea","year":"2011","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.biomaterials.2021.121258_bib56","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1038\/s41467-020-18603-5","article-title":"Combinatorial entropy behaviour leads to range selective binding in ligand-receptor interactions","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2021.121258_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.biomaterials.2021.121258_bib58","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.molpharmaceut.5b00302","article-title":"Antibody-drug conjugates (ADCs): magic bullets at last","volume":"12","author":"Lambert","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2021.121258_bib59","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/open.201900038","article-title":"Efficient bioactive oligonucleotide\u2010protein conjugation for cell\u2010targeted cancer therapy","volume":"8","author":"Avi\u00f1\u00f3","year":"2019","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.biomaterials.2021.121258_bib60","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708772","article-title":"Selective depletion of metastatic stem cells as therapy for human colorectal cancer","volume":"10","author":"C\u00e9spedes","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biomaterials.2021.121258_bib61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.actbio.2021.06.001","article-title":"Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines","volume":"130","author":"\u00c1lamo","year":"2021","journal-title":"Acta Biomater."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961221006153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961221006153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:02:49Z","timestamp":1777485769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961221006153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":61,"alternative-id":["S0142961221006153"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121258","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"121258"}}